APO RESEARCH · REPORT
Antibody-drug Conjugates
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
Product & engineering
Understand the product.
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
Selected research
Industry Research
Antibody-drug Conjugates Industry Research Report 2026
Market perspective
Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
North America is the largest market with about 59% market share. Europe is follower, accounting for about 27% market share.
The key players are ImmunoGen, Seattle Genetics, Roche, Takeda etc. Takeda is the largest manufacturer with about 57% revenue market share.
Read the full market overview
Report Scope
This report quantifies the global Antibody-drug Conjugates market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antibody-drug Conjugates Market by Company
ImmunoGen
Seattle Genetics
Roche
Takeda
Antibody-drug Conjugates Segment by Type
Adcetris
Kadcyla
Antibody-drug Conjugates Segment by Application
Breast Cancer
Lymphoma
Antibody-drug Conjugates Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-drug Conjugates market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antibody-drug Conjugates and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-drug Conjugates.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antibody-drug Conjugates manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antibody-drug Conjugates by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antibody-drug Conjugates in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Adcetris
- Kadcyla
Applications
- Breast Cancer
- Lymphoma
Companies covered
- ImmunoGen
- Seattle Genetics
- Roche
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antibody-drug Conjugates Market Size (2021-2032)
- 2.2.2 Global Antibody-drug Conjugates Sales (2021-2032)
- 2.2.3 Global Antibody-drug Conjugates Market Average Price (2021-2032)
- 2.3 Antibody-drug Conjugates by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Adcetris
- 2.3.3 Kadcyla
- 2.4 Antibody-drug Conjugates by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Breast Cancer
- 2.4.3 Lymphoma
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antibody-drug Conjugates Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antibody-drug Conjugates Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global Antibody-drug Conjugates Revenue of Manufacturers (2021-2026)
- 3.4 Global Antibody-drug Conjugates Average Price by Manufacturers (2021-2026)
- 3.5 Global Antibody-drug Conjugates Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antibody-drug Conjugates, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antibody-drug Conjugates, Product Type & Application
- 3.8 Global Manufacturers of Antibody-drug Conjugates, Established Date
- 3.9 Global Antibody-drug Conjugates Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ImmunoGen
- 4.1.1 ImmunoGen Company Information
- 4.1.2 ImmunoGen Business Overview
- 4.1.3 ImmunoGen Antibody-drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 ImmunoGen Antibody-drug Conjugates Product Portfolio
- 4.1.5 ImmunoGen Recent Developments
- 4.2 Seattle Genetics
- 4.2.1 Seattle Genetics Company Information
- 4.2.2 Seattle Genetics Business Overview
- 4.2.3 Seattle Genetics Antibody-drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Seattle Genetics Antibody-drug Conjugates Product Portfolio
- 4.2.5 Seattle Genetics Recent Developments
- 4.3 Roche
- 4.3.1 Roche Company Information
- 4.3.2 Roche Business Overview
- 4.3.3 Roche Antibody-drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Roche Antibody-drug Conjugates Product Portfolio
- 4.3.5 Roche Recent Developments
- 4.4 Takeda
- 4.4.1 Takeda Company Information
- 4.4.2 Takeda Business Overview
- 4.4.3 Takeda Antibody-drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Takeda Antibody-drug Conjugates Product Portfolio
- 4.4.5 Takeda Recent Developments
5 Global Antibody-drug Conjugates Market Scenario by Region
- 5.1 Global Antibody-drug Conjugates Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antibody-drug Conjugates Sales by Region: 2021-2032
- 5.2.1 Global Antibody-drug Conjugates Sales by Region: 2021-2026
- 5.2.2 Global Antibody-drug Conjugates Sales by Region: 2027-2032
- 5.3 Global Antibody-drug Conjugates Revenue by Region: 2021-2032
- 5.3.1 Global Antibody-drug Conjugates Revenue by Region: 2021-2026
- 5.3.2 Global Antibody-drug Conjugates Revenue by Region: 2027-2032
- 5.4 North America Antibody-drug Conjugates Market Facts & Figures by Country
- 5.4.1 North America Antibody-drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antibody-drug Conjugates Sales by Country (2021-2032)
- 5.4.3 North America Antibody-drug Conjugates Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Antibody-drug Conjugates Market Facts & Figures by Country
- 5.5.1 Europe Antibody-drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antibody-drug Conjugates Sales by Country (2021-2032)
- 5.5.3 Europe Antibody-drug Conjugates Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Antibody-drug Conjugates Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antibody-drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antibody-drug Conjugates Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antibody-drug Conjugates Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antibody-drug Conjugates Market Facts & Figures by Country
- 5.7.1 South America Antibody-drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antibody-drug Conjugates Sales by Country (2021-2032)
- 5.7.3 South America Antibody-drug Conjugates Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Antibody-drug Conjugates Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antibody-drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antibody-drug Conjugates Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antibody-drug Conjugates Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Antibody-drug Conjugates Sales by Type (2021-2032)
- 6.1.1 Global Antibody-drug Conjugates Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global Antibody-drug Conjugates Sales Market Share by Type (2021-2032)
- 6.2 Global Antibody-drug Conjugates Revenue by Type (2021-2032)
- 6.2.1 Global Antibody-drug Conjugates Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antibody-drug Conjugates Revenue Market Share by Type (2021-2032)
- 6.3 Global Antibody-drug Conjugates Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antibody-drug Conjugates Sales by Application (2021-2032)
- 7.1.1 Global Antibody-drug Conjugates Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global Antibody-drug Conjugates Sales Market Share by Application (2021-2032)
- 7.2 Global Antibody-drug Conjugates Revenue by Application (2021-2032)
- 7.2.1 Global Antibody-drug Conjugates Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antibody-drug Conjugates Revenue Market Share by Application (2021-2032)
- 7.3 Global Antibody-drug Conjugates Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antibody-drug Conjugates Value Chain Analysis
- 8.1.1 Antibody-drug Conjugates Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antibody-drug Conjugates Production Mode & Process
- 8.2 Antibody-drug Conjugates Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antibody-drug Conjugates Distributors
- 8.2.3 Antibody-drug Conjugates Customers
9 Global Antibody-drug Conjugates Analyzing Market Dynamics
- 9.1 Antibody-drug Conjugates Industry Trends
- 9.2 Antibody-drug Conjugates Industry Drivers
- 9.3 Antibody-drug Conjugates Industry Opportunities and Challenges
- 9.4 Antibody-drug Conjugates Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst